Close Menu

ASCO

Researchers found that some molecularly defined subsets of patients responded to targeted drugs while others didn't.

Ease Up

Some cancer researchers are pushing to relax clinical trial eligibility requirements, according to Nature.

An impetus for the review included the fact that companies are advertising and promoting liquid biopsy in areas where the technology has not yet proven its clinical utility.

The deal will accelerate delivery of high-quality, deidentified clinical databases to CancerLinQ, its oncologist subscribers, partners, and the broader cancer community.

The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.

Some aspects of testing practice seem clear, while others present significant challenges for clinicians, according to discussions at the recent ASCO meeting.

The researchers described gut microbial diversity and composition differences in metastatic melanoma patients who did or did not respond to immunotherapy. 

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.

American Society of Clinical Oncology presentations show the unmet need for methods to predict autoimmune toxicities in checkpoint blockade-treated individuals.

Pages